Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
about
Second-line treatment of metastatic gastric cancer: Current options and future directionsMitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives.Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study.Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.Second-line chemotherapy for patients with advanced gastric cancer.Latest developments and emerging treatment options in the management of stomach cancer.New perspectives in the treatment of advanced or metastatic gastric cancer.Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).Survivin and XIAP expression in distinct tumor compartments of surgically resected gastric cancer: XIAP as a prognostic marker in diffuse and mixed type adenocarcinomas.Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways.Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer.
P2860
Q26778027-AD186CFF-71CD-4F75-8FE8-B4F6B640FF53Q31156315-974D41E0-51C7-4FFB-BCB8-D492B054DBAEQ33400558-CD1B1FA4-3F6C-48F6-89C4-9F0ED33A39A5Q33413448-B82F25C4-C2EB-4A65-86F7-F0D913A1F086Q35233550-E3485344-458C-438E-BC4C-A6A4DC011028Q38750633-ED81E8E3-28C6-4DDB-BBA9-193A4A68CB0FQ41898734-1A37E6DA-2EA6-49A1-B181-6293590AE07BQ43112721-6944A109-DCAE-4FA5-BE0A-50A821A27160Q46076346-97B0BB4A-C0AA-48C1-BA99-E2DE8DC62DFAQ47101674-60904D3D-E493-43CB-9EB4-8F6705068CC6Q47114485-B7B0DC43-5E68-4069-8096-225D56842E15Q55155589-EFF95DA1-1132-4EAB-BB66-799C62E1CB9D
P2860
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Irinotecan (CPT-11) and mitomy ...... alia Meridionale (prot. 2106).
@ast
Irinotecan (CPT-11) and mitomy ...... alia Meridionale (prot. 2106).
@en
type
label
Irinotecan (CPT-11) and mitomy ...... alia Meridionale (prot. 2106).
@ast
Irinotecan (CPT-11) and mitomy ...... alia Meridionale (prot. 2106).
@en
prefLabel
Irinotecan (CPT-11) and mitomy ...... alia Meridionale (prot. 2106).
@ast
Irinotecan (CPT-11) and mitomy ...... alia Meridionale (prot. 2106).
@en
P2093
P1476
Irinotecan (CPT-11) and mitomy ...... alia Meridionale (prot. 2106).
@en
P2093
C Battaglia
Evaristo Maiello
Francesco Giuliani
Gianluca Vinciarelli
Giuseppe Colucci
Gruppo Oncologico dell' Italia Meridionale (prot. 2106)
Maurizio Di Bisceglie
Nicola Gebbia
Stefano Molica
P304
P356
10.1097/01.COC.0000190398.52142.7F
P577
2005-12-01T00:00:00Z